CRISPR Therapeutics AG (CRSP)
51.53
-0.07
(-0.14%)
USD |
NASDAQ |
Jun 09, 15:15
CRISPR Therapeutics Research and Development Expense (Quarterly) : 66.37M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 961.60M |
| BeOne Medicines Ltd. | 521.31M |
| AC Immune SA | 14.99M |
| Idorsia Ltd. | 33.91M |
| ADC Therapeutics SA | 19.88M |